Article
Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Pharmacogenetics and genomics - 1 May 2007
Inglis Sally C, Herbert Megan K, Davies Benjamin J L, Coller Janet K, James Heather M, Horowitz John D, Morris Raymond G, Milne Robert W, Somogyi Andrew A, Sallustio Benedetta C
Abstract excerpt
AIMS: This study investigated the effects of increasing doses of rac-perhexiline maleate and CYP2D6 phenotype and genotype on the pharmacokinetics of (+) and (-)-perhexiline. METHODS: In a prospective study, steady-state plasma concentrations of (+) and (-)-perhexiline were quantified in 10 CYP2D6 genotyped patients following dosing with 100 mg/day rac-perhexiline maleate, and following a subsequent dosage...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.